Bench to Bedside: How Suzetrigine May Reshape Acute Pain Care in Pharmacy Practice
by Hollie C. Smith, 2027 PharmD Candidate
Abstract:
Acute pain is among the most common conditions managed by pharmacists, yet existing therapies are limited by safety concerns, organ toxicity, and opioid-related risks. The January 2025 U.S. Food and Drug Administration approval of suzetrigine, a first-in-class selective Nav1.8 voltage-gated sodium channel inhibitor, introduces a novel non-opioid option that may shift acute pain management for short-term treatment of moderate to severe acute pain. Inspired by congenital pain insensitivity linked to SCN9A and SCN10A mutations, suzetrigine acts peripherally to inhibit pain signaling without engaging opioid receptors or cyclooxygenase pathways. Phase 2 and Phase 3 postoperative pain trials in abdominoplasty and bunionectomy demonstrated clinically meaningful analgesia versus placebo, with a safety profile characterized primarily by mild gastrointestinal or neurologic adverse effects, without respiratory depression or sedation. Although efficacy was not superior to hydrocodone/acetaminophen, suzetrigine offers an alternative for patients who cannot tolerate nonsteroidal anti-inflammatory drugs or prefer to avoid opioids. Practical considerations include scheduled dosing, cytochrome P450 3A-mediated drug interactions, reduced hormonal contraceptive efficacy, and avoidance in significant hepatic or renal impairment. Pharmacists are well-positioned to provide patient counseling, assess drug interactions, support protocol development, and integrate suzetrigine into multimodal analgesia strategies. Ongoing research, including head-to-head comparisons, real-world cost-effectiveness analyses, evaluations of access and affordability barriers, and exploration of potential applications in chronic pain, will further define its role in therapy. Suzetrigine's introduction represents a meaningful expansion of the acute pain toolbox and an opportunity to advance pharmacist-led opioid stewardship.
Download PDF
2026 May/June Table of Contents
Abstract:
Acute pain is among the most common conditions managed by pharmacists, yet existing therapies are limited by safety concerns, organ toxicity, and opioid-related risks. The January 2025 U.S. Food and Drug Administration approval of suzetrigine, a first-in-class selective Nav1.8 voltage-gated sodium channel inhibitor, introduces a novel non-opioid option that may shift acute pain management for short-term treatment of moderate to severe acute pain. Inspired by congenital pain insensitivity linked to SCN9A and SCN10A mutations, suzetrigine acts peripherally to inhibit pain signaling without engaging opioid receptors or cyclooxygenase pathways. Phase 2 and Phase 3 postoperative pain trials in abdominoplasty and bunionectomy demonstrated clinically meaningful analgesia versus placebo, with a safety profile characterized primarily by mild gastrointestinal or neurologic adverse effects, without respiratory depression or sedation. Although efficacy was not superior to hydrocodone/acetaminophen, suzetrigine offers an alternative for patients who cannot tolerate nonsteroidal anti-inflammatory drugs or prefer to avoid opioids. Practical considerations include scheduled dosing, cytochrome P450 3A-mediated drug interactions, reduced hormonal contraceptive efficacy, and avoidance in significant hepatic or renal impairment. Pharmacists are well-positioned to provide patient counseling, assess drug interactions, support protocol development, and integrate suzetrigine into multimodal analgesia strategies. Ongoing research, including head-to-head comparisons, real-world cost-effectiveness analyses, evaluations of access and affordability barriers, and exploration of potential applications in chronic pain, will further define its role in therapy. Suzetrigine's introduction represents a meaningful expansion of the acute pain toolbox and an opportunity to advance pharmacist-led opioid stewardship.
Download PDF
2026 May/June Table of Contents